Ascendis Pharma A/SASNDEarnings & Financial Report
Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.
ASND Q4 2025 Key Financial Metrics
营收
$267.3M
毛利润
$241.8M
营业利润
N/A
净利润
N/A
毛利率
90.5%
营业利润率
N/A
净利率
N/A
同比增长
42.3%
资金流向
Ascendis Pharma A/S Q4 2025 Financial Summary
Ascendis Pharma A/S reported revenue of $267.3M (up 42.3% YoY) for Q4 2025, with a net profit of N/A (N/A margin). Cost of goods sold was $25.5M.
Key Financial Metrics
| Total Revenue | $267.3M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 90.5% |
| Operating Margin | N/A |
| Report Period | Q4 2025 |
Ascendis Pharma A/S Annual Revenue by Year
Ascendis Pharma A/S annual revenue history includes year-by-year totals (for example, 2025 revenue was $777.7M). Click any linked year to see what changed vs the prior 10-K.
Ascendis Pharma A/S Quarterly Revenue & Net Profit History
Ascendis Pharma A/S quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $267.3M | +42.3% | N/A | N/A |
| Q3 2025 | $230.7M | +269.4% | $-65.9M | -28.5% |
| Q2 2025 | $170.7M | +339.0% | $-42.0M | -24.6% |
| Q1 2025 | $109.0M | +5.3% | $-102.2M | -93.7% |
| Q4 2024 | $187.8M | +26.3% | N/A | N/A |
| Q3 2024 | $62.5M | +20.4% | $-107.1M | -171.5% |
| Q2 2024 | $38.9M | -24.0% | $-118.1M | -303.9% |
| Q1 2024 | $103.6M | +185.5% | $-141.5M | -136.6% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $103.6M | $38.9M | $62.5M | $187.8M | $109.0M | $170.7M | $230.7M | $267.3M |
| 同比增长 | 185.5% | -24.0% | 20.4% | 26.3% | 5.3% | 339.0% | 269.4% | 42.3% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $866.7M | $819.0M | $1.18B | $1.27B | $1.15B | $1.17B | $1.25B | $1.41B |
| 总负债 | $1.12B | $1.17B | $1.29B | $1.39B | $1.35B | $1.38B | $1.44B | $1.58B |
| 股东权益 | $-257.2M | $-346.8M | $-105.1M | $-114.2M | $-205.0M | $-202.6M | $-188.0M | $-175.8M |
现金流量表
| Q1 2024 | Q4 2024 | Q1 2025 | Q4 2025 | |
|---|---|---|---|---|
| 经营性现金流 | $-109.7M | $-330.7M | $-15.5M | $58.2M |